Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Wall-Street-ai7-1

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CTKB

EVTL

HSAI

TRAW

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November

Crude-oil-4-logo

Earnings

Equities

QMCO

Crude Oil Gains 1%; Chicago PMI Falls In December

Super Micro Computer, Bakkt Holdings, MARA Holdings, Microstrategy, And Tesla Inc: Why These 5 Stocks Are On Investors' Radars Today

Movers

CNCK

FWRD

MESO

MVST

RADX

VEON

VNET

Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday

Cytek Biosciences Inc

Press Releases

Cytek Biosciences Reports Third Quarter 2024 Financial Results

General

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

Cytek® Biosciences Named "Overall BioTech Company of the Year" in 2024 BioTech Breakthrough Awards Program

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

Health Care

Cytek Biosciences to Participate in Upcoming Investor Conferences

Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

ChromaDex

Codexis

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Cytek Biosciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga